Hannah Steele

Contributor

tags: Nephrology Oncology Rare Diseases Biomarkers Development Microbiome Research Omics Research Pharma 4.0 (Digital Tech and Data Analytics) Pharmaceutical Manufacturing Pharmacogenomics and Personalized Medicine Pharmacology and Toxicology Database Digital Technologies Pharma 4.0

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

N4 Pharma highlights potential of Nuvec® as gene therapy delivery platform

A pre-clinical in-vivo study found that Nuvec^®– N4 Pharma’s novel silica-based nanoparticle – formulated with TNF-α pDNA oncotherapy, suppressed tumour growth and improved survival of treated mice compared to untreated controls.

Scitara™ Digital Lab Exchange DLX™ Gains ISO Certification and Advances the Modern Lab with the Latest Release of its Barrier-Breaking Lab Integration Platform

Scitara Corporation, an innovator in scientific laboratory digital transformation, announces new releases to its Scitara Digital Lab Exchange DLX™ cloud platform to bring next generation connectivity, self-enabled system configuration, and automation to the lab.

New Independent Market Research Says 84% of US Healthcare professionals likely to use Orviglance Imaging Agent in Target Population

PreOmics Announces Closing of Series B Financing to Accelerate Research, Development and Commercialization of Proteomics Tools and Consumables

PreOmics Offers Unique Technologies, Advanced Automation Solutions and High-Performance
Consumables for the Homogenization, Enrichment and Sample Preparation of Biopsy, Tissue,
Cell Line and Plasma Samples in Unbiased, Deep Proteomics for Biopharma and Clinical Research

Scitara Corp. launches new breakthrough industry Scientific Integration Platform™ to support laboratory digital transformation

Scitara Corporation has launched its new Scientific Integration Platform ™ (SIP™) that presents a solution to the lab connectivity challenges and allows true data mobility.

PreOmics launches BeatBox at ASMS 2021 for high throughput tissue homogenization

Bruker Announces New Microbiology Products and Workflows for Microbial Identification and Infection Control at ECCMID 2021

New MBT Lipid Xtract™ Kit (RUO)* expands MALDI Biotyper® microbial analysis capabilities to lipids fingerprinting and to rapid colistin-resistance testing**
Enhanced workflows include MBT FAST™ Shuttle IVD and MBT Mycobacteria Kit (RUO)**
MALDI Biotyper® Reference Libraries expansion to cover more than 4,000 species
New IR Biotyper® 3.1 software connects MALDI Biotyper® microbial species identification with IR Biotyper® strain-typing results for hospital hygiene**

Scitara Corporation unleashes universal connectivity to redefine lab of the future

Universal data connectivity for life science laboratories delivers seamless digital ecosystem and full automation of lab workflows – with the goal of accelerating scientific discovery

MOBILion Systems Launches MOBIE®: The First SLIM-Based High-Resolution Ion Mobility (HRIM) Product to Accelerate Biotherapeutic Drug Development and Multiomic Biomarker Discovery

Chadds Fords, PA, June 15th, 2021: MOBILion Systems Inc. has today announced the launch of its first commercial High-Resolution Ion Mobility (HRIM) product, MOBIE, which addresses characterization challenges faced during biopharmaceutical drug development and quality monitoring. MOBIE provides fast, efficient separations with superior resolution and reproducibility, faster, simpler method development, and greater instrument uptime. This highly anticipated new technology will help accelerate and simplify the workflows of challenging analyte classes including peptides, proteins, lipids and glycans, with analysis times 5-60 times faster than conventional separation methods.

Key milestone in molded glass: SGD Pharma elevates Type I offering with three tailored product and service solutions

Strengthened value propositions represent the latest step in SGD Pharma’s commitment to continuous improvement